Company Profile
Zevra Stock Price, News & Catalysts
- Ticker:
- ZVRA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
11.87 USD (-0.17%)
Close
Last updated: August 21, 2026
643M USD
Market cap
Why the stock is moving
The latest monitored company update is “Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4).” The corresponding closing-price reaction is not yet available.
Company overview
Rare-Disease Commercial Platform
Zevra Therapeutics is a commercial-stage company focused on therapies for rare diseases. Its operating model combines direct commercialization, global patient-access programs and development of treatments for small, underserved populations.
MIPLYFFA
MIPLYFFA, or arimoclomol, is FDA approved with miglustat for neurological manifestations of Niemann-Pick disease type C in patients two years and older. Zevra also operates a global expanded-access program and has submitted a European marketing application.
OLPRUVA
OLPRUVA is an approved formulation of sodium phenylbutyrate for certain urea-cycle disorders, giving Zevra a second commercial product in inherited metabolic disease.
Celiprolol
Celiprolol is an investigational treatment for vascular Ehlers-Danlos syndrome. The event-driven Phase 3 DiSCOVER trial is being conducted under an FDA Special Protocol Assessment.
Future catalysts
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Zevra (ZVRA)?
Zevra (ZVRA) most recently closed at 11.87 USD, a -0.17% move versus the previous session.
What is the market cap of Zevra (ZVRA)?
Zevra currently has a market capitalization of 643M USD on BioPharmSignal.
What does Zevra do?
Rare-Disease Commercial Platform Zevra Therapeutics is a commercial-stage company focused on therapies for rare diseases. Its operating model combines direct commercialization, global patient-access programs and development of treatments for small, underserved populations. MIPLYFFA MIPLYFFA, or arimoclomol, is FDA approved with miglustat for neurological...
On which exchange is ZVRA stock listed?
Zevra (ZVRA) is associated with NASDAQ, United States, Biopharma.
What is miglustat?
MIPLYFFA MIPLYFFA, or arimoclomol, is FDA approved with miglustat for neurological manifestations of Niemann-Pick disease type C in patients two years and older.
Which conditions is Zevra targeting with miglustat?
Zevra is associated with rare disease, metabolic disease based on its company overview and current catalyst commentary.
What is Rare-Disease?
Rare-Disease Commercial Platform Zevra Therapeutics is a commercial-stage company focused on therapies for rare diseases.
What is Commercial?
Rare-Disease Commercial Platform Zevra Therapeutics is a commercial-stage company focused on therapies for rare diseases.